AEO for Depo-Provera lawsuit lawyers in 2026 means structuring your firm’s case pages, attorney entities, and Google Business Profile so ChatGPT, Perplexity, Google AI Overviews, Google AI Mode, and Microsoft Copilot name your firm when a woman diagnosed with meningioma asks whether she has a claim against Pfizer. The window is unusually sharp right now: MDL 3140 in the Northern District of Florida held roughly 6,294 pending lawsuits as of August 2026, and on June 15, 2026 Pfizer, Pharmacia LLC, and Pharmacia & Upjohn reached a settlement in principle with plaintiffs’ lead counsel that Pfizer estimates could resolve about 80 percent of pending MDL cases. Settlement news drives a query surge, and most firms have no page positioned to catch it.
Three data points define the claim universe. A March 2024 BMJ study of French health system data found prolonged use of injectable medroxyprogesterone acetate associated with roughly a 5.6 times increased risk of intracranial meningioma, which is the scientific spine of the litigation. The FDA approved a meningioma warning for the Depo-Provera label in December 2025, which reset the notice timeline that defense counsel argues about. And beyond the federal MDL, state court inventories continue to build, with roughly 337 cases in Delaware, 132 in New York, and 118 claims in California state court. Claimants researching all of this are not reading law firm brochures. They are asking an AI engine what a meningioma diagnosis means and whether the shot caused it.
What makes Depo-Provera different from other mass tort AEO?
Depo-Provera queries are medical before they are legal, which changes the content that gets cited. Most mass tort searches start with a product name. This one starts with a diagnosis: women search “what causes meningioma,” “is meningioma benign,” and “birth control shot brain tumor” long before they search for an attorney.
That gap is the opportunity. The pages currently answering diagnosis level queries belong to the Mayo Clinic, Cleveland Clinic, the National Cancer Institute, the American Brain Tumor Association, and the Brain Tumor Network. Those sources explain the tumor and stop. They do not explain the medication association, the FDA label change, the MDL posture, or what a claimant does next. A firm page that bridges medical fact to legal option, with the BMJ finding and the December 2025 FDA action both cited by name, occupies ground nobody else is holding.
The second difference is settlement timing. In a litigation with a settlement in principle already announced, the dominant query shifts from “do I have a case” to “am I still eligible” and “how much will I get.” Firms that only publish intake bait miss both. Our AEO for mass tort firms guide covers the general framework this practice area builds on.
Which Depo-Provera queries actually produce AI answers?
Engines answer medical mechanism, eligibility, and procedural posture questions readily, and answer “which lawyer is best” almost never. Build against the four families that generate answers.
1. Causation and mechanism queries
“Does Depo-Provera cause brain tumors,” “how does medroxyprogesterone affect meningioma,” “what is the risk with long term use.” Answer with the actual finding and its limits. The BMJ analysis associated prolonged use, generally understood as use beyond about one year, with a materially elevated meningioma risk, and it did not find the same association for several other progestogens studied. Stating the boundary of the science makes the page more citable, not less.
2. Eligibility and criteria queries
“Who qualifies for a Depo-Provera lawsuit,” “how long did I need to be on the shot,” “does my tumor type count.” Publish the general criteria pattern that has emerged: a documented meningioma diagnosis, records establishing injection history over a sustained period, and a diagnosis timeline consistent with exposure. Name the imaging and record types that establish each.
A meningioma diagnosis sends someone to an AI engine before it sends them to a law firm. Get your free AI visibility audit and see whether ChatGPT and Perplexity name your firm on Depo-Provera and meningioma queries.
3. Litigation status queries
“What is the status of the Depo-Provera MDL,” “is there a settlement yet,” “when is the first trial.” This is where firms win or lose in a settling litigation, because the answer changes monthly and almost nobody maintains the page. Publish the MDL number, the district, the pending case count with the month attached, the June 15, 2026 settlement in principle and the fact that terms remain undisclosed and not finalized, and the pending September 2026 hearing. Date every figure and update it.
4. Statute of limitations and timing queries
“How long do I have to file a Depo-Provera claim,” “is it too late.” Statutes vary by state and the discovery rule interacts with the December 2025 label change in ways that matter. Explain the concept accurately, name the variation by jurisdiction, and tell readers the honest thing: that timing analysis requires a lawyer looking at their specific dates.
How should firms write about a settlement in principle?
Write about it precisely, because imprecision here is both an ethics problem and a citation problem. A settlement in principle is not a settlement. Terms including eligibility criteria, the total amount, and the claims process were still being memorialized as of August 2026, and Pfizer’s own estimate that the deal could resolve roughly 80 percent of pending MDL cases means a meaningful share of claims continue through the court process.
Say all of that plainly. Then explain the three things claimants actually want to know and that almost no firm page addresses: that no per claimant payout figure has been disclosed, that settlement values in a matrix settlement typically vary by injury severity and exposure duration rather than paying a flat number, and that cases outside the MDL in Delaware, New York, and California state courts sit on separate tracks.
Never publish a projected settlement value for an individual claim. Beyond the state bar exposure, engines are aggressively filtering legal pages that promise amounts, and a single number of that kind can suppress the entire domain in medical and legal retrieval. The firms getting cited in this litigation are the ones publishing posture, not projections.
What page architecture gets a mass tort firm cited?
Build a hub with dated satellite pages rather than one long page you rewrite quarterly. The hub carries the durable explanation: what Depo-Provera is, what meningioma is, what the science shows, who the defendants are, and what MDL 3140 is. Satellite pages carry the volatile material: a status update page rebuilt monthly with the current case count and hearing calendar, a criteria page, a state by state limitations page, and a medical records page.
Structure each page around the same triad engines reward. Lead with a direct factual answer containing a number. Break the body into labeled buckets an engine can lift ordinally. Name every real entity: Pfizer, Pharmacia & Upjohn, Depo-Provera, depo-subQ provera 104, the FDA, the Judicial Panel on Multidistrict Litigation, MDL 3140, and the Northern District of Florida. Close with a 5 to 6 question FAQ block so each answer becomes its own retrievable unit.
Attorney entity signals decide ties. Every attorney handling these cases needs Person schema, bar admissions, MDL leadership or committee roles if any, published CLE or article credits, and consistent sameAs links to Avvo, Martindale-Hubbell, Justia, and LinkedIn. Engines resolve firms as entities through repeated co-occurrence across independent sources, so a firm cited in trade coverage of the litigation carries a signal no amount of on-site copy replicates. Our publication tiers guide explains which outlets carry that weight.
Why do most mass tort pages fail to get cited?
They fail because they are written as intake funnels rather than as reference material, and retrieval systems can tell the difference. A page whose first paragraph is “You may be entitled to compensation. Call now for a free case review” contains no fact to extract, so there is nothing to cite even if the engine crawls it.
The second failure is templated duplication. Firms clone the same mass tort page across dozens of torts and dozens of cities with a find and replace. Google’s scaled content abuse policy targets that pattern directly, and engines that detect it stop citing the domain rather than the individual page.
The third failure is abandonment. A status page that says “as of March 2026” in August 2026 is worse than no status page, because staleness is a measurable signal and it drags the freshness score of the whole site. If you cannot commit to updating a litigation status page monthly, do not publish one. Publish the durable science and criteria pages instead and let them age gracefully.
Frequently asked questions
What is the current status of the Depo-Provera MDL in 2026?
MDL 3140 in the Northern District of Florida held roughly 6,294 pending lawsuits as of August 2026. On June 15, 2026, Pfizer, Pharmacia LLC, and Pharmacia & Upjohn reached a settlement in principle with plaintiffs’ lead counsel, though terms including eligibility, amount, and the claims process remain undisclosed and not finalized. Pfizer estimates the deal could resolve about 80 percent of pending MDL cases, with remaining claims continuing through the court process.
Does Depo-Provera cause meningioma?
A March 2024 BMJ study of French national health data found prolonged use of injectable medroxyprogesterone acetate associated with roughly a 5.6 times increased risk of intracranial meningioma. The study associated the elevated risk with sustained use rather than short term use, and did not find the same association across several other progestogens examined. In December 2025 the FDA approved a meningioma warning for the Depo-Provera label, which the litigation treats as a notice milestone.
Who qualifies for a Depo-Provera lawsuit?
The general pattern requires a documented meningioma diagnosis supported by imaging, medical or pharmacy records establishing Depo-Provera injection history over a sustained period, and a diagnosis timeline consistent with that exposure. Statutes of limitation vary by state and interact with discovery rule analysis, which the December 2025 FDA label change complicates. Eligibility under the pending MDL settlement in principle has not been publicly defined, so criteria may shift.
How should a law firm write about a settlement in principle?
Precisely and without projecting values. State that a settlement in principle is not a finalized settlement, that terms remain undisclosed, and that a share of claims will continue litigating. Never publish an estimated per claimant payout, because outcome promises create state bar exposure and AI engines actively downweight legal pages that quote settlement amounts. Publishing accurate posture, dated monthly, is what earns citations in an active litigation.
What content gets a mass tort firm cited by ChatGPT and Perplexity?
Pages that pair a checkable fact with a named entity and a date. That means naming Pfizer, Pharmacia & Upjohn, the FDA, MDL 3140, and the Northern District of Florida explicitly, citing the BMJ finding and the December 2025 label action by name, and attaching a month to every case count. Intake-first pages that open with “you may be entitled to compensation” contain nothing extractable, so engines have nothing to quote.
How often should a litigation status page be updated?
Monthly, or not published at all. Case counts, hearing dates, bellwether schedules, and settlement posture in an active MDL change every few weeks, and a status page still citing figures from five months ago damages the freshness signal for the entire domain. If monthly maintenance is not realistic, publish durable science, criteria, and limitations pages instead and let a single dated status line point readers to the JPML statistics directly.
Settlement news moves fast and the firms already indexed as authoritative are the ones AI engines quote. Run a free AI visibility audit on your firm and find out where you stand on Depo-Provera and meningioma queries today.
Mass tort visibility is won in the quiet months, not during the news cycle. By the time a settlement is finalized and the query volume triples, the engines have already decided which domains they consider reliable on Depo-Provera, and that decision was made from pages published months earlier with dated numbers, named defendants, and cited science. The firms that treat their case pages as reference material rather than intake forms will be the ones named in the answer. The rest will be paying for clicks on a query that no longer produces them.
Tagged